DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

Phase 2

Conditions: Toxicity
Non-small Cell Lung Cancer

First Posted Date: 2010-09-01

Last Posted Date: 2010-09-03

Lead Sponsor: Fudan University

Target Recruit Count: 68

Registration Number: NCT01192243

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma

Phase 2

Conditions: Sarcoma
Chemotherapy

First Posted Date: 2010-09-01

Last Posted Date: 2010-09-01

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT01192633

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Apatinib

First Posted Date: 2010-08-06

Last Posted Date: 2015-09-09

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT01176669

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab QW, Trastuzumab Q3W

First Posted Date: 2010-07-27

Last Posted Date: 2010-07-27

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT01170143

Locations: 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Abraxane and Cisplatin combination

First Posted Date: 2010-06-24

Last Posted Date: 2012-08-07

Lead Sponsor: Fudan University

Target Recruit Count: 73

Registration Number: NCT01149798

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Minimally Invasive Esophagectomy (MIE) in Prone Versus Left Decubitus Position

Phase 2

Conditions: Esophageal Cancer
Esophagectomy

First Posted Date: 2010-06-15

Last Posted Date: 2011-03-08

Lead Sponsor: Fudan University

Target Recruit Count: 2

Registration Number: NCT01144325

Locations: 🇨🇳
Zhong Shan Hospital, Fu Dan University, Shanghai, China

Study of Urinary Angiotensinogen as a Marker to Warn the Deterioration of Renal Function in CKD Patients Early.

Conditions: Chronic Kidney Disease
Urinary Angiotensinogen

First Posted Date: 2010-05-06

Last Posted Date: 2010-05-06

Lead Sponsor: Fudan University

Target Recruit Count: 400

Registration Number: NCT01118494

Locations: 🇨🇳
Nephrology Department of Huashan Hospital, Shanghai, Shanghai, China

Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy

Phase 4

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: Transcatheter arterial chemoembolization (TACE)
Drug: Telbivudine

First Posted Date: 2010-04-13

Last Posted Date: 2010-04-13

Lead Sponsor: Fudan University

Target Recruit Count: 80

Registration Number: NCT01102335

Locations: 🇨🇳
Liver cancer institute, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Metastasis, Neoplasm

Interventions: Drug: Arm C
Drug: Arm A
Drug: Arm B

First Posted Date: 2010-02-17

Last Posted Date: 2015-03-06

Lead Sponsor: Fudan University

Target Recruit Count: 94

Registration Number: NCT01069081

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Phase 2

Conditions: Rectal Cancer

Interventions: Drug: Oxaliplatin
Drug: Capecitabine
Radiation: Radiotherapy
Procedure: Surgery

First Posted Date: 2010-02-09

Last Posted Date: 2012-03-14

Lead Sponsor: Fudan University

Target Recruit Count: 240

Registration Number: NCT01064999

Locations: 🇨🇳
Cancer Hospital, Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy